Trials / Available
AvailableNCT05448170
Linerixibat Compassionate Use for Cholestatic Pruritus Adult Patients With Primary Biliary Cholangitis (PBC)
Linerixibat Compassionate Use for Cholestatic Pruritus in Adult Patients With Primary Biliary Cholangitis
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The goal of this compassionate use program is to provide a mechanism to supply linerixibat, on an individual named patient basis. This program is for treatment of individuals who have cholestatic pruritus associated with PBC who are deemed at high risk of a significant clinical event as a result of their pruritus and for whom all available pharmaceutical treatment options for cholestatic pruritus have been unsuccessful or are considered to not be appropriate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Linerixibat | open label investigational product |
Timeline
- First posted
- 2022-07-07
- Last updated
- 2025-02-27
Source: ClinicalTrials.gov record NCT05448170. Inclusion in this directory is not an endorsement.